Fibroblast growth factor (FGF) signaling regulates cell proliferation, differentiation, survival,
angiogenesis, and wound healing. Compelling evidence for deregulated FGF signaling in …

Small bowel cancers account for 3% of all gastrointestinal malignancies and small bowel
adenocarcinomas represent a third of all small bowel cancers. Rarity of small bowel …

Colorectal cancer (CRC) remains a leading cause of cancer-related deaths in the United
States. Although immunotherapy has dramatically changed the landscape of treatment for …

Background Metastatic DNA mismatch repair-deficient (dMMR)/microsatellite instability-high
(MSI-H) colorectal cancer has a poor prognosis after treatment with conventional …

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Colon Cancer focuses on systemic therapy options for the treatment of metastatic …

Purpose Fluorouracil/leucovorin as the sole therapy for metastatic colorectal cancer (CRC)
provides an overall survival of 8 to 12 months. With an increase in surgical resections of …

This selection from the NCCN Guidelines for Rectal Cancer focuses on management of
malignant polyps and resectable nonmetastatic rectal cancer because important updates …

PURPOSE Nivolumab received US Food and Drug Administration approval as a single
agent or in combination with ipilimumab in patients with microsatellite instability …

Purpose The primary goal of this study was to evaluate whether pathologic response to
chemotherapy predicts patient survival after preoperative chemotherapy and resection of …

Purpose We investigated the efficacy of fluorouracil (FU), leucovorin, irinotecan, and
bevacizumab (FOLFIRI+ B) in a phase II trial in patients previously untreated for metastatic …